JP2015522018A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522018A5 JP2015522018A5 JP2015520304A JP2015520304A JP2015522018A5 JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5 JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015520304 A JP2015520304 A JP 2015520304A JP 2015522018 A5 JP2015522018 A5 JP 2015522018A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound according
- acceptable salt
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US61/665,951 | 2012-06-29 | ||
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| US61/779,099 | 2013-03-13 | ||
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522018A JP2015522018A (ja) | 2015-08-03 |
| JP2015522018A5 true JP2015522018A5 (Direct) | 2016-08-04 |
| JP6127136B2 JP6127136B2 (ja) | 2017-05-10 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015520304A Active JP6127136B2 (ja) | 2012-06-29 | 2013-06-20 | フェノキシエチルピペリジン化合物 |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| TWI636046B (zh) * | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| AU2014366361B2 (en) | 2013-12-17 | 2017-04-20 | Eli Lilly And Company | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| ES2893452T3 (es) | 2017-05-18 | 2022-02-09 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| ES2887041T3 (es) | 2017-05-18 | 2021-12-21 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de PGE2 |
| DK3625224T3 (da) | 2017-05-18 | 2021-11-08 | Idorsia Pharmaceuticals Ltd | N-substituerede indolderivater |
| EP3889134B1 (en) * | 2019-01-22 | 2024-09-25 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| MXPA04005555A (es) * | 2002-03-18 | 2005-05-16 | Pfizer Prod Inc | Procedimientos de tratamiento con agonistas selectivos del receptor ep4. |
| PL378342A1 (pl) * | 2003-01-10 | 2006-03-20 | F. Hoffmann-La Roche Ag | Pochodne 2-piperydonu jako agoniści prostaglandyn |
| KR100747401B1 (ko) | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| US20050105732A1 (en) * | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| WO2005105733A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| WO2005105732A1 (en) * | 2004-05-04 | 2005-11-10 | Pfizer Japan Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| ES2392192T3 (es) | 2006-04-24 | 2012-12-05 | Merck Canada Inc. | Derivados de indol amida como antagonistas del receptor EP4 |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| BRPI0912778B1 (pt) | 2008-05-14 | 2019-04-30 | Astellas Pharma Inc. | Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CN107693518A (zh) | 2010-02-22 | 2018-02-16 | 株式会社ＡｓｋＡｔ | Ep‑4受体拮抗剂在治疗il‑23介导疾病中的用途 |
| CN103097358B (zh) * | 2010-09-21 | 2015-04-08 | 卫材R&D管理有限公司 | 药物组合物 |
| KR101760164B1 (ko) * | 2011-07-04 | 2017-07-20 | 로타팜 바이오테크 에스.알.엘 | Ep4 수용체 길항제로서 사이클릭 아민 유도체 |
| WO2013004291A1 (en) * | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
-
2013
- 2013-06-13 AR ARP130102076 patent/AR091429A1/es active IP Right Grant
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/ar active
- 2013-06-14 TW TW102121220A patent/TWI599561B/zh active
- 2013-06-20 MX MX2014015953A patent/MX345324B/es active IP Right Grant
- 2013-06-20 EA EA201492255A patent/EA024392B1/ru not_active IP Right Cessation
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/xx unknown
- 2013-06-20 HR HRP20171515TT patent/HRP20171515T1/hr unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 PT PT137342481T patent/PT2867207T/pt unknown
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/ko active Active
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en not_active Ceased
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/es active IP Right Grant
- 2013-06-20 PL PL13734248T patent/PL2867207T3/pl unknown
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/zh active Active
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 MA MA37686A patent/MA37686B1/fr unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/pt active IP Right Grant
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
- 2013-06-20 SI SI201330755T patent/SI2867207T1/sl unknown
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/lt unknown
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/me unknown
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/ja active Active
- 2013-06-20 UA UAA201413598A patent/UA114325C2/uk unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/sr unknown
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/es active Active
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/es unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/fr unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/es unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/es unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/es unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/es unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/es unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009B1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522018A5 (Direct) | ||
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2016508134A5 (Direct) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| JP2016527217A5 (Direct) | ||
| JP2016536286A5 (Direct) | ||
| JP2015522589A5 (Direct) | ||
| JP2019515908A5 (Direct) | ||
| SI2932970T1 (en) | Antiviral therapy | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2014502641A5 (Direct) | ||
| JP2016522254A5 (Direct) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2016510326A5 (Direct) | ||
| JP2019505529A5 (Direct) | ||
| RU2017103656A (ru) | Производные изоиндолинона, полезные в качестве противовирусных средств | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| JP2015522033A5 (Direct) | ||
| JP2015516419A5 (Direct) | ||
| RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами | |
| RU2017134285A (ru) | Борсодержащие низкомолекулярные соединения как антипротозойные агенты |